Quality of life after whole brain radiotherapy compared with radiosurgery of the tumor bed: results from a randomized trial

• Published in: Clinical & translational oncology 2018-02, Vol.20 (2), p.150-159
• Main Authors: Kepka, L., Tyc-Szczepaniak, D., Osowiecka, K., Sprawka, A., Trąbska-Kluch, B., Czeremszynska, B.
• Format: Article
• Language: English
• Subjects: Medicine; Medicine & Public Health; Oncology; Research Article
• ISSN: 1699-048X; 1699-3055
• DOI: 10.1007/s12094-017-1703-5

Background A recent randomized trial (NCT01535209) demonstrated no difference in neurocognitive function between stereotactic radiotherapy of the tumor bed (SRT-TB) and whole brain radiotherapy (WBRT) in patients with resected single brain metastasis. Patients treated with SRT-TB had lower overall survival compared with the WBRT arm. Here, we compared the health-related quality of life (HRQOL) in patients who received WBRT vs. SRT-TB. Methods A self-reported questionnaire was used to assess HRQOL (EORTC QLQ-C30 with the QLQ-BN20 module) before RT, 2 months after RT, and every 3 months thereafter. HRQOL results are presented as mean scores and compared between groups. Results Of 59 randomized patients, 37 (64%) were eligible for HRQOL analysis, 15 received SRT-TB, and 22 had WBRT. There were no differences between groups in global health status and main function scales/symptoms (except for drowsiness and appetite loss, which were worse with WBRT 2 months after RT). Global health status decreased 2 and 5 months after RT, but significantly only for SRT-TB ( p  = 0.025). Physical function decreased significantly 5 months after SRT-TB ( p  = 0.008). Future uncertainty worsened after RT, but significantly only for SRT-TB after 2 months ( p  = 0.036). Patients treated with WBRT had significant worsening of appetite, hair loss, and drowsiness after treatment. Conclusions Despite higher symptom burden after WBRT attributed to the side effects of RT (such as appetite loss, drowsiness, and hair loss), global health status, physical functioning, and future uncertainty favored WBRT compared with SRT-TB. This may be related to the compromised brain tumor control with omission of WBRT.